Prevention and Control of Safety Risks of Traditional Chinese Medicine Based on Indirect Knowledge of Toxicity

doi:10.19803/j.1672-8629.2021.11.02

Abstract

Abstract: For a long time, our knowledge of and research on the safety of traditional Chinese medicine(TCM) have been confined to the inherent toxicity of drugs. However, safety incidents of non-toxic traditional Chinese medicine have been frequently reported in recent years. It is often difficult to make scientific explanations and formulate effective prevention and control measures by evaluating inherent toxicity or direct toxicity alone. Based on the current knowledge and research findings of indirect toxicity of TCM, we recommended strategies for prevention and control of safety risks. We focused on explanation of the difference between indirect toxicity and intrinsic toxicity or immunogenicity. We also discussed how to evaluate and prevent safety risks of TCM effectively in order to provide new ideas and countermeasures for guiding clinical safety and rational use of medicines and promoting the healthy development of traditional Chinese medicine.

Key words: indirect hepatotoxicity, traditional Chinese medicine, safety evaluation, risk prevention and control

CLC Number:

R994.1

GAO Yunjuan, ZHAO Xu, BAI Zhaofang, WANG Jiabo, ZHAN Xiaoyan, GUO Yuming, XIAO Xiaohe. Prevention and Control of Safety Risks of Traditional Chinese Medicine Based on Indirect Knowledge of Toxicity[J]. Chinese Journal of Pharmacovigilance, 2021, 18(11): 1004-1008.

References

[1] Xiao XH.Study and thought on the safety of traditional chinese medicines under healthy China strategy[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2018, 43(5): 857-860.
[2] Xiao XH, Bai ZF, Wang JB, et al.Traditional Chinese medicine (TCM) safety evaluation and pharmacovigilance[J]. Chinese Science Bulletin(科学通报), 2021, 66(Z1): 407-414.
[3] Zheng J.The literature study on the regularity of the herbal toxicity of commonly used chinese herbs[D]. Shandong: Shandong University of Traditional Chinese Medicine, 2010.
[4] Hoofnagle JH, Björnsson ES.Drug-induced liver injury-types and phenotypes[J]. The New England Journal of Medicine, 2019, 381(3): 264-273.
[5] Li CP, Rao T, Chen XP, et al.HLA-B*35:01 allele is a potential biomarker for predicting polygonum multiflorum-induced liver injury in humans[J]. Hepatology, 2019, 70(1): 346-357.
[6] He LZ, Yin P, Meng YK, et al.Immunological synergistic mechanisms of trans-/cis-stilbene glycosides in Heshouwu-related idiosyncratic liver injury[J]. Science Bulletin, 2017, 62(11): 748-751.
[7] National Medical Products Administration. Adverse Drug Reaction Information Bulletin(72 issues)[EB/OL].(2016-12-09) [2021-04-16]. https://www.cdr-adr.org.cn/drug_1/aqjs_1/drug_aqjs_xxtb/201612/t20161209_36818.html.
[8] National Medical Products Administration. Adverse Drug Reaction Information Bulletin(16 issues) [EB/OL].(2008-12-16) [2021-04-16]. https://www.cdr-adr.org.cn/drug_1/aqjs_1/drug_aqjs_xxtb/200812/t20081216_36882.html.
[9] Bai ZF, Gao Y, Wang JB, et al.Evaluation and risk control of idiosyncratic liver injury caused by traditional Chinese medicine[J]. Progress in Pharmaceutical Sciences(药学进展), 2020, 44(10): 724-729.
[10] Gao Y, Wang ZL, Tang JF, et al.New incompatible pair of TCM: epimedii folium combined with psoraleae fructus induces idiosyn-cratic hepatotoxicity under immunological stress conditions[J]. Frontiers of Medicine, 2020, 14(3): 68-80.
[11] Wang ZL, Xu G, Wang HB, et al.Icariside Ⅱ, a main compound in Epimedii Folium, induces idiosyncratic hepatotoxicity by enhancing NLRP3 inflammasome activation[J]. Acta Pharmaceutica Sinica B, 2020, 10(9): 1619-1633.
[12] Xiao XH. The new england journal of medicine“highlights”: drug-induced liver injury types and phenotypes[EB/OL].(2019-07-22) [2021-04-16]. https://mp.weixin.qq.com/s/YxJom99NPQ13SqiFbbJ8ag.
[13] Gao Y.Safety and rational drug use strategy of traditional Chinese medicine based on clinic[J]. Chinese Journal of Integrated Traditional and Western Medicine(中国中西医结合杂志), 2019, 39(2): 140-143.
[14] Nociti V, Biolato M, De Fino C, et al.Liver injury after pulsed methylprednisolone therapy in multiple sclerosis patients[J]. Brain and Behavior, 2018, 8(6): e00968.
[15] Ghabril M, Bonkovsky HL, Kum C, et al. Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases[J]. Clinical Gastroenterology and Hepatology, 2013, 11(5): 558-564.e3.
[16] Huffman BM, Kottschade LA, Kamath PS, et al.Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma: natural progression and management[J]. American Journal of Clinical Oncology, 2018, 41(8): 760-765.
[17] Zen Y, Yeh MM.Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury[J]. Modern Pathology, 2018, 31(1): 965-973.
[18] Peng B, Lloyd P, Schran H.Clinical pharmacokinetics of imatinib[J]. Clinical Pharmacokinetics, 2005, 44(9): 879-894.
[19] Yang N, Chen J, Hou XF, et al.Individualized clinical treatment from the prospective of hepatotoxicity of non-toxic traditional Chinese medicine[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2017, 42(7): 1407-1413.
[20] Han JM, Yee J, Cho YS, et al.Factors influencing imatinib-induced hepatotoxicity[J]. Cancer Research and Treatment, 2020, 52(1): 181-188.
[21] Meng M, Zhuang YH, Song CF, et al.Advances in the pathogen of drug-induced liver injury[J]. World Latest Medicine Information (Electronic Version)(世界最新医学信息文摘), 2017, 17(68): 66-68.
[22] Bai ZF, Gao Y, Zuo XB, et al.Progress in research on the pat-hogenesis of immune regulation and idiosyncratic drug-induced liver injury[J]. Acta Pharmaceutica Sinica(药学学报), 2017, 52(7): 1019-1026.
[23] Li CY, Li XF, Tu C, et al.The idiosyncratic hepatotoxicity of Polygonum multiflorum based on endotoxin model[J]. Acta Pharmaceut Sinica(药学学报), 2015, 50(1): 28-33.
[24] Zhang L, Niu M, Wei AW, et al.Risk profiling using metabolomic characteristics for susceptible individuals of drug-induced liver injury caused by Polygonum multiflorum[J]. Archives of Toxicology, 2020, 94(1): 245-256.
[25] Chen YY, Sui H, Zhang L, et al.Review of‘Internal heat'caused by taking ginseng[J]. World Science and Technology/Modernization of Traditional Chinese Medicine and Materia Medica(世界科学技术—中医药现代化), 2018, 20(4): 597-602.
[26] Hu YP.Investigating toxicity grading of toxic traditional Chinese medicine and summaring experience about using toxic traditional Chinese medicine of Professor Peng Wannian[D]. Guangzhou: Guang-zhou University of Chinese Medicine(广州中医药大学), 2015.
[27] Cao M, Wu B, Ma D, et al.Metabolomics study on Fructus Xanthii-induced hepatotocity in rats[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2011, 13(5): 287-293.
[28] Wang JB, Cui HR, Bai ZF, et al.Precision medicine-oriented safety assessment strategy for traditional Chinese medicines: Disease-syndrome-based toxicology[J]. Acta Pharmaceut Sinica(药学学报), 2016, 51(11): 1681-1688.
[29] Xiao XH, Li XH, Zhu Y, et al.Guideline for diagnosis and treatment of herb-induced liver injury[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2016, 41(7): 1165-1172.
[30] Shen CY, Wu TT, Liu W, et al.Post-marketing surveillance and evaluation of Chinese drugs in the new Era[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(10): 649-652, 675.
[31] Xiao XH.Combination of medicine and pharmacy assists for precise prevention and control of drug-induced liver injury[J]. Journal of Clinical Hepatology(临床肝胆病杂志), 2020, 36(3): 489-490.
[32] Wang JB, Ma ZJ, Niu M, et al.Evidence chain-based causality identification in herb-induced liver injury: exemplification of a well-known liver-restorative herb Polygonum multiflorum[J]. Frontiers of Medicine, 2015, 9(4): 457-467.
[33] Branch of Chinese Patent Medicine, Chinese Association of Chinese Medicine. Guidelines for safe use of Polygoni Multiflori Radix[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2020, 45(5): 961-966.
[34] Xiao XH, Tang JF, Mao YM, et al.Guidance for the clinical evaluation of traditional Chinese medicine-induced liver injury issued by China Food and Drug Administration[J]. Acta Pharmaceut Sin B, 2019, 9(3): 648-658.
[35] Zhang XM, Xu MD, Chen WG, et al.Research on national sentinel alliance for adverse drug reaction surveillance based on CHPS[J]. Chinese Pharmaceutical Affairs(中国药事), 2019, 33(2): 137-142.
[36] National Medical Products Administration. NMPA Launched China's Drug Regulatory Scientific Action Plan [EB/OL].(2019-04-30) [2021-04-16]. http://www.nmpa.gov.cn/WS04/CL2056/3371.
[37] Cai HD.Focus on liver injury caused by traditional Chinese medicine and related health products[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2018, 20(3): 161-163.
[38] Zhang YH, Zhao KW, Liu LX, et al.Zhou Chaofan discusses the potential adverse reactions of non-toxic traditional Chinese medicine[J]. Journal of Basic Chinese Medicine(中国中医基础医学杂志), 2017, 23(4): 544-545, 560.